$1.8 B

MYGN Mkt cap, 10-Jun-2019

Myriad Genetics Revenue Breakdown

Embed Graph

Myriad Genetics revenue breakdown by business segment: 93.1% from Diagnostics and 6.9% from Other

Myriad Genetics Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018

Revenue

740.5m769.9m772.6m

Revenue growth, %

2%4%0%

Cost of goods sold

157.3m171.2m177.2m

Gross profit

583.2m598.7m595.4m

Gross profit Margin, %

79%78%77%

R&D expense

70.6m74.4m70.8m

General and administrative expense

359.2m476.4m467.1m

Operating expense total

429.8m550.0m476.7m

EBIT

153.4m48.7m118.7m

EBIT margin, %

21%6%15%

Interest expense

300.0k6.0m3.2m

Interest income

900.0k1.2m1.8m

Pre tax profit

156.0m40.9m116.9m

Income tax expense

38.8m20.6m(14.0m)

Net Income

117.2m20.3m130.9m

Myriad Genetics Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

68.5m102.4m110.9m

Accounts Receivable

91.7m90.2m98.3m

Prepaid Expenses

18.4m12.7m9.4m

Inventories

38.3m42.2m34.3m

Current Assets

314.5m301.7m326.4m

PP&E

58.3m51.1m43.2m

Goodwill

195.3m316.1m318.6m

Total Assets

880.5m1.2b1.2b

Accounts Payable

21.1m22.0m26.0m

Current Liabilities

72.3m217.5m102.2m

Long-term debt

99.1m9.3m

Total Debt

99.1m9.3m

Total Liabilities

132.4m440.9m209.2m

Common Stock

700.0k700.0k700.0k

Additional Paid-in Capital

830.1m851.4m915.4m1.1b

Retained Earnings

(73.2m)(78.2m)52.9m

Total Equity

748.1m768.0m964.9m

Debt to Equity Ratio

0.1 x0 x

Debt to Assets Ratio

0.1 x0 x

Financial Leverage

1.2 x1.6 x1.2 x

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

87.4m134.7m120.5m86.9m108.1m123.8m87.9m88.7m97.4m93.3m90.6m

Accounts Receivable

83.4m84.3m91.1m98.2m107.6m114.8m113.2m121.1m123.7m119.1m116.6m

Prepaid Expenses

5.6m9.7m21.1m12.2m12.1m9.5m9.5m9.8m10.1m11.5m12.5m

Inventories

34.3m29.1m25.3m53.9m51.3m47.4m38.9m38.2m33.4m35.9m33.3m

Current Assets

307.3m375.5m372.4m322.9m341.6m348.3m325.6m327.0m331.5m341.9m336.8m

PP&E

64.9m61.7m60.0m56.8m54.7m53.0m49.8m48.4m48.2m60.0m59.1m

Goodwill

177.3m177.0m177.9m312.8m315.4m315.0m319.0m319.4m320.2m413.3m413.2m

Total Assets

787.0m871.7m868.2m1.3b1.3b1.3b1.2b1.2b1.2b1.6b1.6b

Accounts Payable

15.8m16.5m13.8m19.9m22.9m26.8m22.5m25.1m20.2m23.8m31.9m

Short-term debt

199.2m

Current Liabilities

59.0m65.9m66.1m274.9m82.8m221.7m139.2m159.3m94.3m108.0m113.3m

Long-term debt

204.0m167.1m74.2m43.2m69.3m258.0m273.3m

Total Debt

199.2m204.0m167.1m74.2m43.2m69.3m258.0m273.3m

Total Liabilities

99.9m100.9m98.0m535.6m543.4m519.9m357.7m314.3m270.1m471.4m492.5m

Common Stock

700.0k700.0k700.0k700.0k700.0k700.0k700.0k700.0k700.0k700.0k700.0k

Additional Paid-in Capital

772.3m847.8m847.0m826.9m831.8m839.5m859.6m871.1m889.6m1.1b1.0b1.1b

Retained Earnings

(78.8m)(68.6m)(69.2m)(86.5m)(85.7m)(81.4m)12.8m44.8m56.2m53.4m22.9m

Total Equity

687.1m770.8m770.2m735.3m732.7m747.9m870.6m914.2m948.4m1.1b1.1b

Debt to Equity Ratio

0.3 x0.3 x0.2 x0.1 x0 x0.1 x0.2 x0.3 x

Debt to Assets Ratio

0.2 x0.2 x0.1 x0.1 x0 x0.1 x0.2 x0.2 x

Financial Leverage

1.1 x1.1 x1.1 x1.7 x1.7 x1.7 x1.4 x1.3 x1.3 x1.4 x1.5 x

Myriad Genetics Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Depreciation and Amortization

26.8m48.3m54.4m73.0m

Accounts Receivable

(25.9m)(39.9m)(39.2m)

Inventories

(14.6m)(1.2m)7.9m8.0m

Accounts Payable

(3.0m)4.0m

Cash From Operating Activities

166.3m106.2m115.9m

Cash From Investing Activities

(91.4m)(146.3m)(11.6m)

Long-term Borrowings

(305.0m)(143.0m)

Cash From Financing Activities

(68.3m)71.8m(95.0m)

Net Change in Cash

4.4m33.9m8.5m

Free Cash Flow

161.3m100.1m107.5m

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Depreciation and Amortization

6.8m13.5m20.0m9.2m22.1m35.0m13.2m26.3m39.3m18.3m36.3m

Accounts Receivable

(3.6m)(11.1m)(28.7m)(5.9m)(24.4m)(40.3m)(6.2m)(13.0m)(42.3m)(3.3m)(900.0k)

Inventories

(9.2m)(4.1m)(200.0k)(13.0m)(10.4m)(6.5m)3.3m4.1m8.9m3.5m6.1m

Accounts Payable

(5.3m)(4.1m)(6.9m)(5.0m)(2.0m)2.0m400.0k3.0m(2.0m)(8.4m)(300.0k)

Cash From Operating Activities

29.8m81.9m127.8m(2.9m)28.5m69.6m23.5m56.5m68.0m7.8m45.6m

Cash From Investing Activities

9.0m(31.5m)(47.6m)(158.0m)(160.1m)(150.6m)(15.2m)(19.8m)(20.5m)(279.0m)(287.1m)

Long-term Borrowings

(200.0m)(237.0m)(25.0m)(56.0m)(83.0m)(40.0m)(75.0m)

Cash From Financing Activities

(15.2m)22.0m(22.0m)175.8m171.8m135.1m(23.3m)(49.4m)(53.7m)252.1m219.5m

Net Change in Cash

23.3m70.6m56.4m18.4m39.5m55.3m(14.5m)(13.7m)(5.0m)(17.6m)(20.3m)

Free Cash Flow

28.8m79.8m125.0m(4.4m)24.6m64.2m21.9m52.8m61.4m6.5m41.5m

Myriad Genetics Operating Metrics

FY, 2016FY, 2017FY, 2018Q1, 2019Jan, 2019

Patients Tested to Date

2 m3 m3 m

Products

11

Tests Performed to Date

4 m

Scientific Publications to Date

1 k

Countries

143

Commercial Payers (Prolaris)

8 9

Commercial Lives Under Coverage (Prolaris)

20 m24 m

Myriad Genetics Employee Rating

3.8222 votes
Culture & Values
3.9
Work/Life Balance
4.1
Senior Management
3.4
Salary & Benefits
3.6
Career Opportunities
3.5
Source